A clinical trial of partially HLA-matched unrelated donor microtransplantation for prevention of relapse in patients with acute myeloid leukaemia ineligible for standard haemopoietic stem cell transplantation

急性髓性白血病在不能接受骨髓移植的患者中预后较差，尤其是老年人。没有证实的治疗方法可以改善他们的不良预后。迫切需要为这组患者找到临床适用的、无毒的治疗方法。我们将进行一项“微移植”的临床试验，使用不相关的干细胞供体联合化疗，以减少这些患者的复发率，同时不产生标准干细胞移植的毒性效应。

Acute myeloid leukaemia has a poor prognosis in patients unable to undergo bone marrow transplant, in particular in the elderly. No proven therapy improves their poor outcome. There is an urgent need to identify clinically applicable, non-toxic therapies for this group of patients. We will perform a clinical trial of "microtransplantation" using unrelated stem cell donors in combination with chemotherapy to try to reduce the relapse rate in these patients without the toxic effects of standard stem cell transplantation.